Acer therapeutics and relief therapeutics announce presentation of acer-001 data at the genetic metabolic dieticians international conference

Newton, ma and geneva, switzerland / accesswire / may 6, 2022 / acer therapeutics inc. (nasdaq:acer) ("acer") and its collaboration partner, relief therapeutics holding sa (six:rlf, otcqb:rlftf, rlfty) ("relief"), today announced the presentation of data evaluating the bioavailability, bioequivalence and taste attributes of acer-001 (sodium phenylbutyrate) compared to sodium phenylbutyrate (buphenyl ® ) powder during poster sessions at the recent genetic metabolic dieticians international (gmdi) conference on may 5, 2022, in las vegas, nevada. "we are pleased to present results from these two studies at another renowned genetic metabolic conference," said adrian quartel, md, cmo of acer.
ACER Ratings Summary
ACER Quant Ranking